The xerostomia therapeutics market is driven by the increasing prevalence of dry mouth, often caused by conditions such as Sjögren's syndrome, diabetes, or as a side effect of medications such as chemotherapy. Xerostomia leads to discomfort, difficulty in speaking and swallowing, and a higher risk of oral infections. The market includes a wide range of products such as artificial saliva, salivary stimulants, and saliva substitutes. Recent developments highlight advancements in drug formulations and oral care products designed to alleviate the symptoms of xerostomia. Companies are focusing on innovations such as non-invasive treatments and natural-based therapies to cater to the growing demand for safer, more effective solutions. The market is also benefiting from increased awareness of oral health and aging populations, which contribute to a higher incidence of xerostomia. With new product approvals and strategic partnerships, the xerostomia therapeutics market is expected to experience significant growth in the coming years.
